A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a dose‐ranging study to evaluate safety of efimosfermin alfa and to establishproof‐of‐concept that efimosfermin alfa therapy provides benefit in participants withALD.
Epistemonikos ID: 9348df313196e85744fec430f7b120441a4f0a34
First added on: Aug 27, 2026